Esophageal Cancer Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Esophageal Cancer market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharmaceuticals, Amgen, Merck Sharp & Dohme LLC, Dana-Farber Cancer Institute, Hoffmann-La Roche, AstraZeneca, Arcus Biosciences, Inc., BeiGene, Seagen Inc.

[Nevada, United States] - DelveInsight's "Esophageal Cancer Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Esophageal Cancer, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Esophageal Cancer Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Esophageal Cancer Market Report:
• The Esophageal Cancer market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Merck Sharp & Dohme LLC announced a Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)
• In October, 2024: Jazz Pharmaceuticals announced a Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
• In September, 2024: Hoffmann-La Roche announced a Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
• In September, 2024: Sichuan Baili Pharmaceutical Co., Ltd. announced a Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy, BL-B01D1+SI-B003 Combination Therapy and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
• According to the Centre for Disease Control and Prevention (CDC) (2022), there were 18,950, 18,669, 18,090 new cases of Esophageal Cancer in 2019, 2018, and 2017, respectively. The CDC reported the number of Esophageal Cancer cases from 1999 to 2019.
• As per Surveillance Epidemiology and End Results Program (SEER) (2022), there were 20,640 new cases of Esophageal Cancer, accounting for 1.1% of all new cancer cases, in 2022.
• Key Esophageal Cancer Companies are as follows: Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharmaceuticals, Amgen, Merck Sharp & Dohme LLC, Dana-Farber Cancer Institute, Hoffmann-La Roche, AstraZeneca, Arcus Biosciences, Inc., BeiGene, Seagen Inc.
• Key Esophageal Cancer Therapies are as follow: CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, Pembrolizumab, Cisplatin, Tislelizumab, Trastuzumab, Bevacizumab, Oxaliplatin, Tiragolumab, Atezolizumab, AZD5863, Domvanalimab, Quemliclustat, Zimberelimab, Tucatinib
• Launching multiple stage Esophageal Cancer pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Esophageal Cancer market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Esophageal Cancer Overview:
Esophageal cancer treatment often involves surgery to remove the cancer. Fluoropyrimidine- and platinum-containing chemotherapy is the cornerstone treatment. Other therapies such as ramucirumab, pembrolizumab, nivolumab, ipilimumab are also recommended either alone or in combination with standard chemotherapeutic regimen.

Esophageal Cancer Epidemiology Segmentation:
The Esophageal Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Esophageal Cancer Total Diagnosed Incident Cases
• Esophageal Cancer Line wise Treated Cases
• Esophageal Cancer Age-specific Cases
• Esophageal Cancer Stage-specific Cases

For more information about Esophageal Cancer companies working in the treatment market, visit https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Esophageal Cancer Market Insights
In cancer care, doctors often work together to create the patient's overall treatment plan combining different treatments. For a tumor that has not spread beyond the esophagus and lymph nodes, the doctors often recommend combining different types of treatment: Radiation therapy, chemotherapy, and surgery. For locally advanced esophageal cancer, treatments often include radiation therapy, chemotherapy, and surgery. Sometimes, chemotherapy and radiation therapy are combined in an approach called "chemoradiotherapy". Treatment for metastatic esophageal cancer usually involves radiation therapy, chemotherapy, and other medication therapies.

Esophageal Cancer Drugs Uptake
• ROZLYTREK (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test, adult and pediatric patients older than 1 month of age with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion
• VITRAKVI (larotrectinib) is a cancer medicine for treating solid tumors with NTRK gene fusion. NTRK gene fusion is a rare genetic abnormality that can occur in tumors from different parts of the body, such as the lungs, thyroid glands, and intestines.
• Zanidatamab is a novel, late-stage oncology asset with the potential to transform the standard of care in multiple HER2-expressing cancers. It has demonstrated compelling data in biliary tract cancers and gastresophageal adenocarcinoma with the potential to benefit patients across multiple tumor types.
• Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Esophageal Cancer Therapies and Key Companies:
• CYRAMZA (ramucirumab): Eli Lilly and Company
• VITRAKVI (larotrectinib): Bayer
• Zanidatamab: Zymeworks/Jazz Pharmaceuticals
• Bemarituzumab: Amgen
• Pembrolizumab, Cisplatin: Merck Sharp & Dohme LLC
• Zanidatamab, Tislelizumab, Trastuzumab: Jazz Pharmaceuticals
• bevacizumab, oxaliplatin: Dana-Farber Cancer Institute
• Tiragolumab, Atezolizumab: Hoffmann-La Roche
• AZD5863: AstraZeneca
• Domvanalimab, Quemliclustat, Zimberelimab: Arcus Biosciences, Inc.
• Cisplatin: BeiGene
• tucatinib, tucatinib: Seagen Inc.

Esophageal Cancer Epidemiology:
Esophageal cancer is a serious and aggressive malignancy affecting the esophagus, the tube that connects the throat to the stomach. Esophageal cancer ranks as the eighth most common cancer worldwide, with more than 600,000 new cases diagnosed annually. In 2023, the World Health Organization (WHO) and Global Cancer Observatory (GLOBOCAN) estimated that esophageal cancer accounted for approximately 3.1% of all cancer cases globally.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Esophageal Cancer Market Drivers:
• Rising Global Incidence of Esophageal Cancer
• Advancements in Targeted Therapies
• Increasing Investment in Research & Development
• Expanding Awareness and Early Diagnosis

Esophageal Cancer Market Barriers:
• High Treatment Costs and Limited Access
• Late Diagnosis and Poor Prognosis
• Complexity of the Disease and Resistance to Therapies
• Side Effects and Toxicity of Current Therapies

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Esophageal Cancer Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Esophageal Cancer Companies: Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharmaceuticals, Amgen, Merck Sharp & Dohme LLC, Dana-Farber Cancer Institute, Hoffmann-La Roche, AstraZeneca, Arcus Biosciences, Inc., BeiGene, Seagen Inc.
• Key Esophageal Cancer Therapies: CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, Pembrolizumab, Cisplatin, Tislelizumab, Trastuzumab, Bevacizumab, Oxaliplatin, Tiragolumab, Atezolizumab, AZD5863, Domvanalimab, Quemliclustat, Zimberelimab, Tucatinib
• Esophageal Cancer Therapeutic Assessment: Current marketed and emerging therapies
• Esophageal Cancer Market Dynamics: Esophageal Cancer Market drivers and Esophageal Cancer barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Esophageal Cancer Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Esophageal Cancer market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Esophageal Cancer Market Overview at a Glance
4. Executive Summary of Esophageal Cancer
5. Key Events
6. Disease Background and Overview
7. Diagnosis
8. Treatment and Management of Esophageal Cancer
9. Methodology
10. Epidemiology and Patient Population
11. Patient Journey
12. Marketed Therapies
13. Emerging Therapies
14. Esophageal Cancer: 7MM Analysis
15. KOL Views
16. SWOT Analysis
17. Unmet Needs
18. Market Access and Reimbursement
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.